A study of AZD2962 in Participants with Haematologic Neoplasms
Research type
Research Study
Full title
A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AZD2962, an IRAK4 inhibitor, as Monotherapy and in Combination with other Agents, in Participants with Haematologic Neoplasms
IRAS ID
1011659
Contact name
David Alanby Johnson
Contact email
Sponsor organisation
AstraZeneca AB
Research summary
This study focuses on blood cancer, particularly myelodysplastic syndromes (MDS) and dysplastic chronic myelomonocytic leukaemia (CMML).
These are blood disorders where the bone marrow does not produce enough healthy blood cells. There is often inflammation in the bone marrow that helps abnormal blood cells survive and grow.
New treatment options are needed for patients with these blood disorders.
The study aims to test a new drug called AZD2962, which is an IRAK4 inhibitor. IRAK4 is a protein involved in immune signalling and inflammation. By blocking IRAK4, researchers hope to reduce inflammation in the bone marrow and potentially treat blood cancer.
The study will assess the safety, how well participants tolerate the drug, how the body processes it, and whether it shows any early signs of effectiveness. To do this, the study will begin by giving a small dose, known as the first dose level, to a limited number of participants and increasing this dose to the next level once it is safe to do so. The study will continue in this way with each dose level checked to see if it is safe. Once the study reaches either the highest dose level planned, or it is not tolerated, the first portion of the study will be completed. More participants may be added to a dose level to gather additional information. Overall, the study plans to enrol approximately 72 participants with MDS and CMML. The study participants will be enrolled across 20 sites in the United Kingdom and six other countries. However, this number may change depending on the study's progress.
The Sponsor of the study is AstraZeneca AB.REC name
South Central - Oxford A Research Ethics Committee
REC reference
25/SC/0146
Date of REC Opinion
12 Jun 2025
REC opinion
Further Information Favourable Opinion